WallStSmart

Haemonetics Corporation (HAE)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 2677% more annual revenue ($37.54B vs $1.35B). MDT leads profitability with a 13.9% profit margin vs 7.1%. HAE appears more attractively valued with a PEG of 1.63. MDT earns a higher WallStSmart Score of 68/100 (B-).

HAE

Hold

50

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 6.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.51

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HAEUndervalued (+34.3%)

Margin of Safety

+34.3%

Fair Value

$87.46

Current Price

$108.40

$20.94 discount

UndervaluedFair: $87.46Overvalued
MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$92.13

$2.30 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HAE0 strengths · Avg: 0/10

No standout strengths identified

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

HAE4 concerns · Avg: 3.8/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

Altman Z-ScoreHealth
1.514/10

Distress zone — elevated risk

Profit MarginProfitability
7.1%3/10

7.1% margin — thin

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HAE

HAE has a balanced fundamental profile.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : HAE

The primary concerns for HAE are PEG Ratio, EPS Growth, Altman Z-Score. A P/E of 49.7x leaves little room for execution misses.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

MDT carries more volatility with a beta of 0.57 — expect wider price swings.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (68/100 vs 50/100) and 13.7% revenue growth. HAE offers better value entry with a 34.3% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Haemonetics Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?